{"id":50340,"date":"2022-06-27T12:52:43","date_gmt":"2022-06-27T11:52:43","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&p=50340"},"modified":"2023-05-25T21:40:23","modified_gmt":"2023-05-25T20:40:23","slug":"benjamin-weingberg-asco-2022","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/colorectal-cancer\/conference-hub\/benjamin-weingberg-asco-2022\/","title":{"rendered":"Benjamin Weinberg, ASCO 2022: Highlights of ASCO in colorectal cancer, dostarlimab and the DYNAMIC study"},"content":{"rendered":"

Professor Benjamin Weinberg <\/b>(Georgetown University, Washington, DC, USA) discusses the highlights of colorectal cancer at ASCO 2022. A subset of colorectal cancer is mismatch repair deficient and is responsive to PD-1 blockade in the metastatic setting. This led to the phase II study where dostarlimab, an anti PD-1 monoclonal antibody, was administered to patients with MicroSatellite Instability-High (MSI-H) localized rectal cancer. Professor Weinberg discusses the excitement around the outcome of this phase II study (0:52). The DYNAMIC study aimed to assess if a circulating tumour DNA (ctDNA)-guided approach could reduce the use of adjuvant chemotherapy without compromising recurrence risk. Professor Weinberg discusses the findings of the DYNAMIC trial and the key takeaways (03:52).<\/p>\n

The abstracts entitled ‘Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer’ (Abstract number LBA5<\/a>) and \u2018Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial\u2019 (Abstract number LBA100<\/a>) were presented at the ASCO<\/a>\u00a0annual meeting,\u00a0June 3-7, 2022.<\/p>\n

Disclosures<\/strong>: Benjamin Weinberg has received grant\/research support from Ipsen, is on the advisory board for Bayer and Taiho and the speaker’s bureau for AstraZeneca, Bayer, Daiichi Sankyo, Eli Lilly, Sirtex and Taiho.<\/p>\n

Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.<\/p>\n

Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO<\/a>) annual meeting.<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Professor Benjamin Weinberg (Georgetown University, Washington, DC, USA) discusses the highlights of colorectal cancer at ASCO 2022. A subset of colorectal cancer is mismatch repair deficient and is responsive to PD-1 blockade in the metastatic setting. This led to the phase II study where dostarlimab, an anti PD-1 monoclonal antibody, was administered to patients with […]<\/p>\n","protected":false},"featured_media":50330,"template":"","class_list":["post-50340","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-colorectal-cancer","video_categories-asco-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/50340"}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":5,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/50340\/revisions"}],"predecessor-version":[{"id":76757,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/50340\/revisions\/76757"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/50330"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=50340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}